Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Traders Purchase Large Volume of Xylem Put Options (NYSE:XYL)

Xylem logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

  • Put-option activity surged: Traders purchased 10,022 Xylem put options, roughly 358% above the typical daily volume, signaling increased hedging or bearish speculation.
  • Weak results and guidance pressured the stock: Third-quarter revenue fell 3% year over year to $2.20 billion and missed expectations, while management cut its 2026 outlook and issued a weak fourth-quarter forecast. Shares dropped to $88.11, near their 52-week low.
  • Analyst sentiment became more cautious: JPMorgan downgraded Xylem to neutral and cut its target to $90, while several firms lowered price targets; despite this, the consensus rating remains “Moderate Buy” with an average target of $129.50.
  • MarketBeat previews top five stocks to own in November.

Xylem Inc. (NYSE:XYL - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 10,022 put options on the stock. This represents an increase of approximately 358% compared to the typical daily volume of 2,188 put options.

Xylem News Roundup

Here are the key news stories impacting Xylem this week:

  • Positive Sentiment: Third-quarter adjusted EPS increased to $1.44 from $1.37 a year earlier, while orders reportedly rose 10%, suggesting some underlying demand resilience. However, these gains were not enough to offset the revenue shortfall and weaker guidance. Xylem Q3 2026 results
  • Positive Sentiment: Stifel Nicolaus retained a “buy” rating with a $114 price target, while Oppenheimer maintained “outperform” at $135. These targets imply substantial recovery potential if Xylem executes its restructuring and business reset. Stifel Nicolaus rating
  • Neutral Sentiment: Xylem plans divestitures and a segment restructuring as part of a portfolio reset. The changes could improve focus and profitability over time, but they also introduce execution risk and may weigh on results in the near term. Xylem outlook and restructuring
  • Negative Sentiment: Revenue fell 3% year over year to $2.20 billion, about $80 million below expectations, and EPS missed consensus. Weak metering demand and project timing pressured sales. Xylem Q3 revenue miss
  • Negative Sentiment: Management lowered its 2026 revenue and profit outlook and issued a weak fourth-quarter forecast, signaling that near-term headwinds are more severe than previously expected. Xylem lowered outlook
  • Negative Sentiment: JPMorgan downgraded Xylem to “neutral” and cut its price target to $90 from $118. RBC also reduced its target to $125, and Oppenheimer lowered its target to $135, reflecting broad estimate revisions. JPMorgan Xylem downgrade
  • Negative Sentiment: Put-option volume surged to more than four times its average, indicating increased hedging or bearish speculation. A law firm also announced an investigation into potential securities-law violations following the earnings-related losses. Xylem investigation notice

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in XYL. Renaissance Investment Group LLC raised its position in Xylem by 5.8% during the 3rd quarter. Renaissance Investment Group LLC now owns 88,230 shares of the industrial products company's stock worth $8,935,000 after buying an additional 4,823 shares during the last quarter. Soltis Investment Advisors LLC acquired a new stake in Xylem during the third quarter valued at $6,895,000. Choreo LLC purchased a new position in Xylem in the third quarter valued at $248,000. North Star Investment Management Corp. increased its holdings in Xylem by 21.4% in the third quarter. North Star Investment Management Corp. now owns 1,701 shares of the industrial products company's stock valued at $172,000 after buying an additional 300 shares in the last quarter. Finally, William Mack & Associates Inc. acquired a new position in shares of Xylem in the third quarter worth about $25,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on XYL shares. Royal Bank Of Canada lowered their price objective on Xylem from $135.00 to $125.00 and set an "outperform" rating on the stock in a research note on Wednesday. UBS Group decreased their price target on Xylem from $138.00 to $112.00 and set a "neutral" rating for the company in a research note on Monday, October 5th. Wolfe Research began coverage on shares of Xylem in a research note on Tuesday, September 15th. They issued a "peer perform" rating for the company. JPMorgan Chase & Co. lowered Xylem from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $118.00 to $90.00 in a report on Wednesday. Finally, Barclays reduced their price objective on shares of Xylem from $159.00 to $139.00 and set an "overweight" rating for the company in a report on Tuesday, October 13th. Ten research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Xylem currently has an average rating of "Moderate Buy" and an average price target of $129.50.

Check Out Our Latest Analysis on XYL

Xylem Stock Performance

Shares of Xylem stock traded down $4.75 during trading hours on Wednesday, reaching $88.11. The company had a trading volume of 6,502,143 shares, compared to its average volume of 2,133,233. The firm has a market cap of $20.57 billion, a PE ratio of 20.94, a price-to-earnings-growth ratio of 1.75 and a beta of 1.00. Xylem has a one year low of $87.40 and a one year high of $154.27. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.61 and a quick ratio of 1.24. The business has a fifty day simple moving average of $106.50 and a 200 day simple moving average of $118.31.

Xylem (NYSE:XYL - Get Free Report) last issued its earnings results on Tuesday, October 27th. The industrial products company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.45 by ($0.01). Xylem had a return on equity of 11.77% and a net margin of 11.15%. The company had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the prior year, the business earned $1.37 EPS. The firm's revenue for the quarter was down 3.0% compared to the same quarter last year. On average, analysts anticipate that Xylem will post 5.65 earnings per share for the current fiscal year.

Xylem Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 24th. Stockholders of record on Thursday, August 27th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Thursday, August 27th. Xylem's dividend payout ratio is presently 40.95%.

About Xylem

(Get Free Report)

Xylem Inc NYSE: XYL is a global water technology company that develops products and services for the transportation, treatment, testing and efficient use of water and wastewater. Its offerings support municipal water and wastewater utilities, industrial customers, commercial facilities and residential applications.

The company's products and solutions include water and wastewater pumps, treatment systems, dewatering equipment, smart meters, monitoring and control technologies, leak detection tools, and data-driven analytics.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Xylem Right Now?

Before you consider Xylem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.

While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines